Purpose To investigate the impact of PET and PET/CT scanning on decision-making in management planning and to identify the optimal setting for selecting candidates for surgery in suspicious recurrent ovarian cancer. Methods A retrospective chart review was performed in patients with possible recurrent ovarian cancer after primary optimal cytoreduction and taxane/carboplatin chemotherapy who had undergone FDG PET or FDG PET/CT scans from July 2002 to August 2008 to help make treatment decisions. The analysis included 44 patients who had undergone a total of 89 PET scans. The positive PET scans were classified as follows.
Introduction
The majority of women with advanced ovarian cancer eventually develop recurrent disease despite achieving a clinical complete remission after initial treatment. With few exceptions, recurrent ovarian cancer patients are unlikely to be cured of their disease. Thus the goal of treatment is to improve the quality of life and lengthen the survival period. Most patients are offered further chemotherapy, although the response is limited. The role of secondary cytoreductive surgery for recurrent ovarian cancer is still controversial.
Several studies have found factors associated with outcome in patients who have undergone secondary cytoreductive surgery. The treatment-free interval (TFI) prior to secondary cytoreductive surgery and residual disease after it have been demonstrated to be associated with better outcome [1, 2] . However, the ratio of patients with optimal resection is as low as 70 % [3] . This might be due to the difficulty in predicting the possibility of attaining optimal cytoreduction. The proper preoperative selection of candidates remains unclear. The purposes of this study were to investigate the impact of PET scan findings (e.g. FDG uptake patterns) on decision making for management planning and to identify the optimal setting for selecting candidates for surgery from among those with suspicion of recurrent ovarian cancer.
Patients and methods
After obtaining Institutional Review Board approval, a retrospective chart review was performed in patients with possible recurrent ovarian cancer who had undergone FDG PET or FDG PET/CT scans between July 2002 and August 2008 at Hokkaido University Hospital. This analysis included 44 patients who had undergone a total of 89 PET scans (60 FDG PET, 29 FDG PET/CT) during this period. All patients had histologically confirmed ovarian cancer and underwent primary optimal cytoreduction and taxane/carboplatin chemotherapy.
The images were reviewed by radiologists with experience in CT and nuclear medicine physicians with experience in PET. Whole-body 18 F-FDG PET imaging was performed using an ECAT EXACT 47 scanner (Siemens-CTI, Knoxville, TN). Before the PET study, all of the patients fasted for at least 6 h, and serum glucose levels were checked before administration of 18 F-FDG. The dose of 18 F-FDG was 185 MBq in each patient. Static emission scans were performed 60 min after 18 F-FDG administration using the threedimensional acquisition mode with a duration of 2 min per bed position. PET/CT imaging was performed using a Discovery LS system (GE Medical Systems, Milwaukee, WI). Patients fasted for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level <200 mg/dl, sterile FDG was administered intravenously (4.5 MBq/kg) followed by a tracer uptake phase of approximately 70 min. Positron emission data were acquired for five to seven bed positions, typically from the base of the skull to the mid-thigh. Emission data were acquired for 3 min for each bed position. PET images were reconstructed using the CT data for attenuation correction using the 2-D OSEM algorithm. The CT portion of the Discovery LS consisted of a multidetector helical CT scanner. Imaging parameters were as follows for an acquisition with five bed positions: 140 mA, 60 mA, 0.6 s per CT rotation.
The standard surveillance protocol for patients with ovarian cancer consists of physical examination and evaluation of serum CA 125 levels at intervals of 2 to about 3 months for the initial 24 months after completion of primary therapy and every 4 months thereafter. Abdominal and chest contrastenhanced CT scans are performed every 6 months. Patients with an increased serum CA 125 (20 U/ml or more) and a negative or equivocal CT scan receive a PET scan. The presence, region and pattern (e.g. nodular, diffuse) of FDG uptake are fully reviewed. A management plan is then discussed. Close observation is recommended for patients who do not have distinct accumulation on PET scans despite an increased CA 125. Systemic chemotherapy is given in patients who show a multiple or diffuse FDG uptake pattern. Otherwise, cytoreductive surgery is proactively considered in patients whose FDG uptake patterns are localized.
The positive PET scans were classified into three categories of FDG uptake pattern: (1) localized (one or two localized sites of FDG uptake, (2) multiple (three or more sites of FDG uptake, each site with nodular uptake), (3) diffuse (extensive low-grade activity outlining serosal and peritoneal surfaces). TFI was defined as the time from completion of initial treatment or any previous recurrent treatment to the time of latest recurrence.
Statistical analyses were carried out using Statistica software (StatSoft, Tulsa, OK). Correlations among the variables were analysed using Fisher's exact test and the chi-squared test. The Kruskal-Wallis test was used for nonparametric variables. P <0.05 was considered statistically significant.
Results
The analysis included 44 patients who had undergone a total of 89 FDG PET scans (20 patients had one scan, 12 patients had two scans, and 12 patients had three or more scans). The indications for PET scanning were abnormal CT findings (48.3 %), a rise in serum CA 125 (37.1 %), suspicion of relapse on physical examination (10.1 %), or clinical symptoms (4.5 %). Most patients (95.5 %) were asymptomatic at the time of the PET scan. Detailed characteristics of the patients are shown in Table 1 . The majority of patients had stage III (65.9 %) and grade 3 (63.7 %) disease at initial Table 2 shows the FDG uptake pattern in relation to the TFI in 82 patients in whom positive FDG uptake was detected. The proportions of patients with a localized pattern with TFI <3 months, 3 to <6 months, 6 to <12 months, and ≥12 months were 36.0 %, 52.9 %, 58.8 % and 78.3 %, respectively. A significantly greater proportion of patients with a TFI ≥6 months had a localized uptake pattern than those with a TFI <6 months (70.0 % vs. 42.9 %; P =0.012). In patients with serous histology, the relationship between serum CA 125 level and FDG uptake pattern was examined. The proportion of patients with a localized FDG uptake pattern decreased as the CA 125 level increased: 77.8 % (14/18) in those with CA 125 ≤50 U/ml, 66.7 % (10/15) in those with CA 125 50 to ≤100 U/ ml, and 41.4 % (12/29) in those with CA 125 >100 U/ml (P = 0.038).
A total of 35 cytoreductive operations were performed in 25 patients. The median patient age was 60 years (range 35 -78 years). The histological types were: serous in 68 % of patients, clear cell in 20 %, endometrioid in 8 % and mucinous in 4 %. The initial FIGO stages were: I in 12 % of patients, II in 12 %, III in 56 % and IV in 20 %. The tumour grades were: 1 in 24 % of patients, 2 in 20 % and 3 in 56 %.
The median TFI prior to cytoreductive surgery was 10 months (range 1 -70 months). The surgical procedures are listed in Table 3 . The results of the cytoreductive operations are shown in Table 4 . In all patients, recurrent tumours preoperatively detected on PET scans were recognized during surgery. No macroscopic tumours that were undetectable on preoperative PET scans were discovered during surgery. However, 22.2 % (6/27) of patients exhibited miliary disease in the abdominal cavity that could not be detected by PET. The TFIs in the patients who had miliary disseminated disease were 6, 6, 6, 7, 8 and 10 months. In addition, a small to modest amount of ascites (<500 ml) was found during surgery in 11.1 % of these patients (3/27) that was not seen preoperatively. All the patients with ascites had miliary disease. Macroscopically complete resection was achieved in 91.4 % of cytoreduction procedures (32/35). On the other hand, following 3 of the 35 procedures (8.6 %), the patient had residual tumour less than 0.5 cm in diameter, and these were the patients who had miliary disease on the peritoneal surface. There were no patients who had residual tumours measuring more than 0.5 cm. Pathological examination confirmed recurrent disease in all patients. The median tumour diameter was 30 mm (range 10 -72 mm). The mean estimated blood loss was 80 ml (range 10 -580 ml). The median operative time was 125 min (range 50 -450 min). There were no severe postoperative complications.
Regarding the 27 intraperitoneal operations, the factors that were related to peritoneal miliary dissemination are shown in Table 5 . Miliary dissemination was detected in 6 (50.0 %) of the 12 patients with a TFI <12 months, compared with none of those with a TFI ≥12 months (P =0.0031). Miliary dissemination was detected in 3 (12.5 %) of the 24 patients with no Fig. 1 Treatment plans before and after PET in patients with suspected recurrent ovarian cancer ascites during the operation, in contrast to this finding in all three patients with measurable ascites (P =0.0068). In addition to these variables, none of the other variables analysed (secondary, tertiary or quaternary cytoreduction, serous or other, grade 1/2 or 3, CA125 <100 U/ml or ≥100 U/ml, one or two recurrent lesions, size of maximum tumour <30 mm or ≥30 mm) predicted miliary disease.
Discussion
In this study, 58 % of PET scans led to a change in the management of the patient. PET scanning was especially useful in selecting candidates for site-specific treatment (e.g. surgery, irradiation). Cytoreductive surgery had a high the rate of complete resection (91 %). Even if a PET scan indicates localized disease, patients with a TFI of ≥12 months are the best candidates for complete resection due to the tumour size limitation. For optimal management in recurrent ovarian cancer, it is necessary to consider the following factors: length of the TFI/platinum-free interval, possible second-line regimens, prior adverse effects experienced by the patient, and patient choice. Several studies have demonstrated that an elevation of serum CA 125 can precede the appearance of clinically or radiographically measurable recurrence by an average of 3 to 6 months [4, 5] . However, early retreatment in asymptomatic patients is still controversial. OV05/EORTC 55955 trials have concluded that there is no survival benefit from early treatment based on an elevated serum CA 125 level alone [6] . On the contrary, investigators have recently reported that the detection of asymptomatic recurrence by routine surveillance testing is associated with a high likelihood of optimal secondary cytoreductive surgery and extended overall survival [7] . During the course of recurrent treatment, several strategies can be used, namely: chemotherapy, cytoreductive surgery and palliative irradiation. To avoid an accumulation of adverse effects of systemic cytotoxic agents (e.g. peripheral neuropathy, myelosuppression), we considered that it would be preferable to offer site-specific therapy for patients with recurrence when possible. Individualized approaches are also essential for a good quality of life and long survival of patients. For instance, patients who show symptoms or massive ascites need immediate treatment. On the other hand, in an asymptomatic patient who shows only rising serum CA 125 levels and negative or equivocal CT scans, a PET scan is strongly recommended. The presence, region and uptake pattern of FDG should be fully reviewed in order to make a decision. The management plan for the patient should then be discussed and confirmed. In some patients, close observation is recommended if there is no distinct accumulation on the PET scan despite elevated serum CA 125. Systemic chemotherapy is given for patients who indicate multiple or diffuse FDG uptake patterns. Otherwise, cytoreductive surgery is strongly considered for patients whose FDG uptake patterns are localized.
The sensitivity and specificity of CA 125 in recurrent ovarian cancer diagnosis are reported to be 57.6 -92.1 % and 71.9 -96.7 %, respectively [8] [9] [10] . And the sensitivity and specificity of PET/CT are 93.3 -97.4 % and 80 -100 %, respectively [11, 12] . A recent meta-analysis of 29 studies demonstrated that PET/CT has high sensitivity (89 %) and specificity (90 %) [13] . Some studies have shown that management plans tend to change after examination of PET scans [14, 15] . Fulham et al. found that the management plan in 58.9 % of patients changed based on PET scan findings. In that study, 38.9 % of the patients finally underwent cytoreductive surgery [16] . In our study, the results of 58.4 % of the PET scans led to a change in management of the patient. The proportions of patients who were treated surgically increased from 13.5 % before PET to 39.3 % after PET. The use of PET/CT in patients with elevated CA 125 levels would lead to more patients being appropriately offered either chemotherapy or surgery.
Patients with localized FDG uptake patterns are the best candidates for surgical therapy. Patients with a TFI of more than 6 months were more likely to have higher localized FDG uptake. Of patients who had a positive PET scan, 78 % exhibited a localized pattern if their TFI was more than 12 months. Whether there is an association between TFI after second recurrence and outcome of the recurrent treatment is still a matter of debate. And there are very limited data published on tertiary surgical cytoreduction [17] . Notably, serum CA 125 levels have been found to be lower in patients with localized FDG uptake than in those with multiple or diffuse patterns. Palomar et al. consider that a PET scan is indicated when the CA 125 level is above 18 U/ml [18] . We observed that the proportion of patients with a positive PET scan was significantly higher (29/35, 82.9 %) when the CA 125 level exceeded 20 U/ml, compared to those with a level lower than 20 U/ml (4/27, 14.8 %; P <0.01; unpublished data). A localized FDG uptake pattern would probably be obtained when (a) the TFI is ≥6 months and (b) there is a successive elevation of serum CA 125 above 20 -30 U/ml. In these patients, cytoreductive surgery should be considered.
A recent meta-analysis has revealed that the optimal level of cytoreduction after secondary cytoreductive surgery is 70.3 % (range, 22.2 -100 %) [3] , although the definition of optimal cytoreduction varied (from <2.5 cm to no gross disease). The proportion of patients with complete resection was lower (52.2 %, range 9.4 -100 %). Multivariate analysis revealed that the proportion of patients with complete cytoreduction and the year of publication were significant predictors of survival. Each 10 % increase in the proportion of patients with complete cytoreductive surgery was associated with a 3-month increase in median cohort survival time. However, disease-free interval and survival were not significantly associated [3] . For tertiary cytoreduction, only residual disease after surgery retained prognostic significance [17] . Consequently, the selection of appropriate candidates is crucial for optimal cytoreduction. The results of our study suggest that the FDG uptake pattern is useful for selecting patients who are suitable for site-specific treatment. In this study, the rate of complete resection was as high as 91.4 %, and median tumour size was small (30 mm). Moreover, there were no severe complications or perioperative mortality. It is reasonable to suppose that we were able to choose optimal candidates using PET scanning and to perform cytoreduction earlier than in previous studies. This may have led to a high complete resection rate and low morbidity. FDG PET scanning produces functional images that reflect increased rates of glucose metabolism in tumour, and it has many pitfalls in clinical use. Many papers in oncology have reported that PET scanning is of limited use in the detection of malignant tumours less than 1 cm in size. In the current study, six patients with localized macroscopic recurrence were also found to have miliary or multiple small lesions (<5 mm). None of these lesions was detected by PET. All patients in whom complete resection was not possible had miliary disease. Size limitations in performing PET scans must be born in mind, since implants <10 mm are inconsistently identified owing to low concentrations and limited spatial resolution [19] . Miliary peritoneal dissemination was significantly associated with a TFI of <12 months and ascites on cytoreduction. Consequently, even if a PET scan indicates localized FDG uptake, whether cytoreductive surgery should be performed in patients with a TFI of <12 months needs careful consideration.
In summary, PET scanning is helpful in optimizing the management plan in patients with recurrent ovarian cancer and in aiding in the selection of appropriate candidates for attempted surgical resection.
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